Atomwise is a pioneering TechBio company that utilizes artificial intelligence and machine learning to transform the field of small molecule drug discovery. The company is renowned for its innovative application of deep learning in structure-based drug design, which forms the backbone of its advanced AI discovery and optimization engine. Atomwise's technology is distinguished by its capability to identify and enhance novel chemical compounds, thereby increasing the chances of developing groundbreaking medicines that can significantly improve patient care. With a proven track record of success in over 230 academic and collaborative projects, Atomwise is actively building a pipeline of small-molecule drug candidates with the potential to be first-in-class and best-in-class, particularly in the area of immunology.